- Home
- MUFG vs JNJ Comparison
MUFG vs JNJ Comparison
Compare MUFG & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | JNJ |
|---|---|---|
| Founded | 1880 | 1886 |
| Country | Japan | United States |
| Employees | 178953 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.2B | 542.4B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | MUFG | JNJ |
|---|---|---|
| Price | $20.10 | $240.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $238.20 |
| AVG Volume (30 Days) | 3.2M | ★ 6.3M |
| Earning Date | 05-15-2026 | 04-14-2026 |
| Dividend Yield | 2.32% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | $6.63 |
| Revenue Next Year | $10.12 | $7.43 |
| P/E Ratio | ★ $25.47 | $111.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.20 | $149.04 |
| 52 Week High | $20.23 | $251.71 |
Technical Indicators
Market Signals| Indicator | MUFG | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 66.65 | 65.80 |
| Support Level | $14.80 | $233.83 |
| Resistance Level | $20.19 | $246.40 |
| Average True Range (ATR) | 0.30 | 4.24 |
| MACD | 0.03 | 1.60 |
| Stochastic Oscillator | 92.36 | 94.32 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.4% share of all domestic loans as of March 2025. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.